期刊文献+

黄斑中心凹下脉络膜新生血管光动力疗法治疗后黄斑区对比敏感度变化 被引量:1

Changes of contrast sensitivity in macular area before and after photodynamic therapy in patients with subfoveal choroidal neovascularization
原文传递
导出
摘要 目的观察黄斑中心凹下脉络膜新生血管(CNV)光动力疗法(PDT)治疗前后对比敏感度(CS)的变化。方法回顾分析29例PDT治疗的患者32只眼治疗前以及治疗后2周、1、3、6个月、1年时视力、对比度视力、CS检查的临床资料。结果治疗后6个月时,视力稳定者占50%,提高者占40.9%,降低者占9.1%。平均高对比度视力均较治疗前有所提高。治疗后2周、3个月时,低频区CS与治疗前相比均有显著性差异(P=0.043、P=0.037)。6个月时,中频区间频率与治疗前比较有显著性差异(P=0.048),高频区间治疗前后均无改变。年龄以及光斑直径对CS无显著影响。结论PDT治疗黄斑中心凹下CNV短期内可改善患者的视力、对比度视力和CS,但是长期随访仍十分必要。 Objective To investigate the changes of contrast sensitivity in macular area of patients with subfoveal choroidal neovascularization (CNV) before and after photodynamic therapy (PDT). Methods The clinical data of 29 consecutive patients (32 eyes) undergone PDT for subfoveal CNV were retrospectively analyzed. The best corrected visual acuity, contrast visual acuity and contrast sensitivity frequency before the treatment and 2 weeks, 1 month, 3 months, 6 months, and 1 year after PDT were inspected. Results Six months after PDT, the best corrected visual acuity kept stable in 50% patients, improved in 40. 9% ,and decreased in 9.1%. The average high-contrast visual acuity was better after PDT than which before PDT. Two weeks and 3 months after PDT, the contrast sensitivity alteration of low spatial frequencies differed significantly from which before the treatment (P = 0. 043, P = 0. 037). Six months after PDT, contrast sensitivity alteration of middling spatial frequencies significantly different from which before the treatment (P= 0. 048); however, no difference of contrast sensitivity of high spatial frequencies before and after PDT was found. Age and light-spot diameter had no distinct influence on contrast sensitivity. Conclusion PDT for subfoveal choroidal neovascularization in macular area may improve the best corrected visual acuity, contrast visual acuity and contrast sensitivity frequency in a short term, however, the long-term fellow-up observation is necessary.
出处 《中华眼底病杂志》 CAS CSCD 北大核心 2007年第1期27-29,共3页 Chinese Journal of Ocular Fundus Diseases
关键词 脉络膜新生血管化/药物疗法 光化学疗法/副作用 激光疗法 小剂量/副作用 治疗结果 对比敏感度 Choroidal neovascularization/drug therapy Photochemotherapy/adverse effects Laser therapy, low-leve/adverse effects Treatment outcome Contrast sensitivity
  • 相关文献

参考文献20

  • 1McClure JA,Hart PM,Jackson AJ,et al.Macular degeneration:do conventional measurements of impaired visual function equate with visual disability? Br J Ophthalmol,2000,84:244-250.
  • 2Rubin GS,Bandeen-Roche K;Huang GH,et al.The association of multiple visual impairments with self-reported visual disability:SEE project.Invest Ophthalmol Vis Sci,2001,42:64-72.
  • 3Donald C,Fletcher MD,Ronald A,et al.Visual function in patients with choroidal neovascularization resulting from agerelated macular degeneration" the importance of looking beyond visual acuity.Optometry and vision science,2006,83:178-189.
  • 4Photodynamictherapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin.Arch Ophthalmol,1999,117:1329-1345.
  • 5陆方,严密,张军军.光动力疗法治疗老年性黄斑变性的临床研究[J].中华眼底病杂志,2002,18(3):175-179. 被引量:18
  • 6Schmidt-ErfurthU,MitlerJW,SichenbergM,et al.Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related degeneration.Arch Ophthalmol,1999,117:1177-1187.
  • 7Armbrecht AM,Aspinall PA,Dhillon BA.Prospective study of visual function and quality of life following PDT in patients with wet age related macular degeneration.Br J Ophthalmol,2004,88:1270-1273.
  • 8夏群,卢颖毅,喻晓兵,龙力,李洁,戴虹.渗出型老年性黄斑变性患者光动力疗法治疗前后视功能变化[J].中华眼底病杂志,2004,20(5):289-291. 被引量:13
  • 9Rubin GS,Bressler NM.Effects of verteporfin therapy on contrast on sensitivity:results from the treatment of age-related macular degeneration with photodynamic therapy (TAP)investigation-TAP report No 4.Retina,2002,22:536-544.
  • 10Barnes RM,Gee L,Taylor S,et al.Outcomes in verteporfin photodynamic therapy for choroidal neovascularisation:beyond the TAP study.Eye,2004,18:809-813.

二级参考文献13

  • 1Treatment of age-related macular degeneration with photodynamic therapy(TAP) study group.Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin.Arch Ophthalmol,1999,117:1329-1345.
  • 2Schmidt-Erfurth U,Mitler JW,Sichenberg M,et al.Photodynamic therapy with verteporfin for choroidal neovascularization caused by age-related degeneration.Arch Ophthalmol,1999,117:1177-1187.
  • 3Macular Photocogulation Study Group. Subfoveal neovascular lesions in age-related macular degeneration. Arch Ophthalmol, 1991, 109: 1242-1257.
  • 4Treatment of Age-related Macular Degeneration with Photodynamic Therapy(TAP) Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Arch Ophthalmol,1999,117:1329-1345.
  • 5TAP Study Group. Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin. Two-year results of 2 randomized clinical trials-TAP report 2. Arch Ophthalmol,2001,119:198-207.
  • 6VIP Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization-verteporfin in p
  • 7VIP Study Group. Verteporfin therapy of subfoveal choroidal neovascularization in pathologic myopia:2-year results of a randomized clinical trial-VIP report No.3.Ophthalmology,2003,110:667-673.
  • 8Rogers AH, Duker JS, Nichols N, et al. Photodynamic therapy of idiopathic and inflammatory choroidal neovascularization in young adults. Ophthalmology,2003,110:1315-1320.
  • 9Schmidt-Erfurth UM, Michels S. Changes in confocal indocyanine green angiography through two years after photodynamic therapy with verteporfin. Ophthalmology, 2003, 110: 1306-1314.
  • 10Schmidt-Erfurth U, Laqua H, Schlotzer- Schrehard U, et al. Histopathological changes following photodynamic therapy in human eyes. Arch Ophthalmol, 2002,120:835-844.

共引文献43

同被引文献15

  • 1魏世辉,周必业.关注神经眼科疾病诊断中的几个热点问题[J].眼科,2006,15(6):366-368. 被引量:9
  • 2Balcer LJ, Baier ML, Cohen JA, et al. Contrast letter acuity as a visual component for the Multiple Sclerosis Functional Composite. Neurology ,2003,61 : 1367-1373.
  • 3Menon V, Mehrotra A, Saxena R, et al. Comparative evaluation of megadose methylprednisolone with dexamethasone for treatment of primary typical optic neuritis. Indian J Ophthalmol,2007 ,55 :355- 359.
  • 4Beck RW, Kupersmith MJ, Cleary PA, et al. Fellow eye abnormalitiesin acute unilateral optic neuritis: experience of the Optic Neuritis Treatment Trial. Ophthalmology, 1993,100: 691- 697.
  • 5Fisher JB, Jacobs DA, Markowitz CE, et al. Relation of visual function to retinal nerve fiber layer thickness in muhiple sclerosis. Ophthalmology,2006,113 : 324-332.
  • 6Steel DHW, Waldock A. Measurement of the retinal nerve fiber layer with scanning laser polarimetry in patients with previous demyelinating optic neuritis. J Neurol Neurosurg Psychiatry, 1998, 64:505 -509.
  • 7Roysarkar TK, Gupta A, Dash R J, et al. Effect of insulin therapy on progression of retinopathy in noninsulin-dependent diabetes mellitus. Am J Ophthalrnol, 1993,115:569-574.
  • 8Sisto D, Trojano M, Vetrugno M, et al. Subclinical visual involvement in multiple sclerosis: A study by MRI, VEPs,frequency-doubling perimetry, standard perimetry, and contrast sensitivity. IOVS,2005,46 : 1264-1268.
  • 9Sanders EACM, Volkers ACV, van der Poel JC, et al. Estimation of visual function after optic neuritis: a comparison of clinical tests Br J Ophthalmol, 1986,70:918-924.
  • 10Cole SR, Beck RW, Moke PS, et al. The national eye institute visual function questionnaire: experience of the ONTF. IOVS, 2000,41 : 1017-1021.

引证文献1

二级引证文献7

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部